Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Temozolomide × Clear all

Phase

Phase 2 37 Phase 1 26 Phase 1/2 17 Phase 3 7 Phase NA 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Completed 4 Unknown 3 Recruiting 2 Active not recruiting 2 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Glioblastoma 1 Astrocytoma 1

Interventions

Gemcitabine 8 Carboplatin 7 Paclitaxel 6 Fluorouracil 6 Cyclophosphamide 6 Cisplatin 6 Docetaxel 5 Capecitabine 5 Stem Cell Transplantation 3 Radiotherapy 3 Pemetrexed 3 Melphalan 3 Leucovorin 3 Etoposide 3 Bevacizumab 3 umbralisib 2 ublituximab 2 fludarabine 2 Vinorelbine 2 Transplantation, Homologous 2 Surveys and Questionnaires 2 S 1 (combination) 2 Oxaliplatin 2 Nivolumab 2 Mitomycin 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡